Measurement and evaluation of serum anti-p53 antibody levels in patients with lung cancer at its initial presentation: a prospective study
1998

Serum Anti-p53 Antibody Levels in Lung Cancer Patients

Sample size: 115 publication Evidence: moderate

Author Information

Author(s): Y Segawal, M Kageyama, S Suzuki, K Jinno, N Takigawa, N Fujimoto, K Hotta, K Eguchi

Primary Institution: National Shikoku Cancer Center Hospital

Hypothesis

The study aims to determine the relationship between anti-p53 antibody levels and clinical features in lung cancer patients.

Conclusion

Serum anti-p53 antibody levels are higher in lung cancer patients compared to normal volunteers and are strongly correlated with tumor histological type.

Supporting Evidence

  • The median anti-p53 antibody index was 6.6 for lung cancer patients compared to 1.7 for normal volunteers.
  • Significant differences in index levels were found by histology.
  • High anti-p53 antibody index levels were observed for both large-cell carcinoma and small-cell carcinoma.

Takeaway

This study found that lung cancer patients have higher levels of a specific antibody in their blood, which could help doctors understand their cancer better.

Methodology

The study measured serum anti-p53 antibody levels using an enzyme-linked immunosorbent assay (ELISA) in 52 lung cancer patients and 63 normal volunteers.

Limitations

The study did not find significant differences in antibody levels based on gender, age, smoking index, or disease stage.

Participant Demographics

52 lung cancer patients (32 men, 20 women, median age 68) and 63 normal volunteers (29 men, 34 women, median age 29).

Statistical Information

P-Value

P = 0.0000

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication